GLP-1 gene delivery for the treatment of type 2 diabetes
US7374930B2 · kind B2 · utility
57Cited by
10References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2002 |
| Grant date | May 20, 2008 |
| Priority date | — |
| Expiry date | Jul 25, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken β actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pβGLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.